Skip to main content
2026 ASCRS Annual Scientific Meeting Main banner
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
Presentation Icons
CME
CME
Invitation/Ticketed Event
Invitation/Ticketed Event
Invited Lectureship
Invited Lectureship
Award Recipient
Award Recipient
Live Streamed Session
Live Streamed Session
Nurses Contact Hours
Nurses Contact Hours
Self-Assessment
Self-Assessment
Live Q&A and Polling
Live Q&A and Polling
Social
Social
Industry
Industry
ViewAttendees 1

Session:: RCTs Galore: The Evidence We Have, The Answers We Don’t

The Anchor Trial and Anal Cancer Prevention: Success, But at What Scale

Tuesday, May 12, 2026
9:14 AM - 9:22 AM ET

    Faculty(s)

  • RM

    Robert D. Madoff, MD, FACS, FASCRS, FRCSEdHon) (he/him/his)

    Stanley M. Goldberg MD Professor emeritus of Colon and Rectal Surgery
    University of Minnesota
    University of Minnesota
    Brooklyn, NY, United States

    All disclosed relationships have been reviewed and managed prior to the start of this activity. Any relevant relationships will be listed below. This individual has no financial relationships to disclose

Individuals living with HIV are at increased risk for anal cancer, and particularly high risk groups have been identified (including men who have sex with men (MSM), transgender women, women with a history of vulvar cancer or pre-cancer, and solid organ transplant recipients.) The 2022 ANCHOR trial demonstrated a substantial reduction in the incidence of anal cancer in HIV positive individuals with documented high-grade anal dysplasia (HSIL) who underwent treatment compared to those who active monitoring. This presentation will discuss the opportunities and challenges of implementing appropriate screening and treatment programs for individuals at high risk for developing anal cancer.